ArticleDiseases (Basel, Switzerland)2026
Histological Evaluation of Insulin-like Growth Factor-I in Experimental Intestinal Ischemia-Reperfusion Injury: A Rat Study.
Article in Diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIntestinal ischemia-reperfusion injury (IRI) remains a major clinical challenge associated with substantial morbidity. Although the biological functions of insulin-like growth factor-I (IGF-I) have been extensively investigated, evidence regarding the direct administration of exogenous recombinant IGF-I in experimental intestinal IRI remains limited. This study evaluated the histological effects of recombinant IGF-I administered at different time points in a rat model of intestinal IRI.
methodsMale Wistar rats underwent 45 min of superior mesenteric artery occlusion followed by 3 h of reperfusion. Animals were allocated to five groups: Sham, untreated Control, and three IGF-I-treated groups receiving intraperitoneal recombinant IGF-I before ischemia, during ischemia, or at reperfusion. Histological injury was assessed using the Chiu grading system (0-5). Data were analyzed using non-parametric statistical methods.
resultsForty-five rats were included in the final analysis. Untreated controls demonstrated the greatest mucosal injury (median Chiu score: 4, IQR: 3-4), whereas Sham-operated animals exhibited minimal injury (median: 0, IQR: 0-1). All IGF-I-treated groups demonstrated lower median histological injury scores (median: 2), with the lowest median observed in the reperfusion group (IQR: 1-3). However, none of the individual comparisons with untreated controls remained statistically significant after Bonferroni correction. A post hoc exploratory pooled analysis demonstrated a similar histological pattern but likewise did not show a statistically significant difference between pooled IGF-I-treated animals and controls after adjustment for multiple comparisons.
conclusionsIn this experimental rat model, exogenous recombinant IGF-I administration was consistently associated with lower histological injury scores than untreated ischemia-reperfusion controls, although a definitive treatment effect could not be established. These findings provide additional experimental evidence regarding the histological effects of recombinant IGF-I in intestinal ischemia-reperfusion injury and support further investigation in larger experimental studies incorporating quantitative histological, molecular, and functional endpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.